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Purpose Drug-induced agranulocytosis is a rare but life-threatening adverse drug reaction. Its 
epidemiology in Chinese is largely unknown. This study aimed to estimate the incidence, mortality, 
and risk of the drugs associated with agranulocytosis in Hong Kong Chinese. Methods A 
population-based case-control study was conducted using the Clinical Data Analysis and 
Reporting System, a database managed by the Hong Kong Hospital Authority. Patients with drug-
induced agranulocytosis from 1 January 2004 to 31 December 2013 were identified. World Health 
Organization causality assessment was used to evaluate the possible drug aetiology of each case. 
Odd ratios (ORs) of the drug exposure were calculated using exact conditional logistic regression. 
Results 155 cases of drug-induced agranulocytosis were identified. Mean age was 51.4 years and 
95 cases were female. Incidence rate was estimated to be 2.2 cases per million person-years and 
the all-cause mortality of patients with drug-induced agranulocytosis was 3.9%. Among the cases, 
the most common associated drug groups were antithyroid drugs (41.9%), antimicrobials (20%), 
anticonvulsants (10.3%), and antipsychotics (6.5%). Carbimazole had the highest risk of 
agranulocytosis (adjusted OR 416.7, 95% Confidence Interval (CI) 51.5 – 3372.9) with an 
incidence of 9.2 (95% CI 6.9 - 12.1) per 10,000 users and 3.6 (95% CI 2.7 - 4.8) per 10,000 user-
years. Other drugs with significant risk included cephalosporins, clozapine, penicillins, phenytoin, 
and propyl thiouracil.  Conclusions The incidence and mortality in Hong Kong Chinese were 
relatively low compared to Caucasians. Antithyroid drugs were the most common implicated drug 




Drug-induced agranulocytosis is a rare adverse drug reaction, clinically defined as absolute 
neutrophil count (ANC) lower than 0.5 x 109/L in circulating blood.1, 2 Due to the extremely low 
neutrophil count, patients with agranulocytosis have a high risk of infection including pneumonia, 
and life threatening sepsis with non-specific preceding symptoms such as fever and sore throat,. 
The reported incidence rate of drug-induced agranulocytosis was 2.4-15.4 cases per million per 
year3 and the mortality was estimated to be 5-9%.4-6 Antithyroid drugs, antimicrobials, and 
antipsychotics have been commonly reported to induce agranulocytosis.3  
A number of epidemiological studies have been conducted in Europe and different results across 
the countries have been reported,4, 5, 7 which could be explained by the differences in drug treatment 
practice and genetic background of the subjects. Population-based study on drug-induced 
agranulocytosis has not been reported in Asians and only few case series reports on antithyroid 
drug-induced agranulocytosis in Chinese8 and Taiwanese9 have been published. The 
epidemiological profile in Chinese is still largely unknown. To fill in this knowledge gap, our 
study aims to estimate the incidence and mortality of drug-induced agranulocytosis in Hong Kong 
Chinese and evaluate the drug aetiology profile and their associated risk estimate with 
agranulocytosis.  
Methods 
The study protocol has been approved by the institutional review boards of the University of Hong 




Clinical data in this study were obtained from the Clinical Data Analysis and Reporting System 
(CDARS), a database managed by the Hong Kong Hospital Authority (HA).10  HA is a publicly 
funded healthcare provider, offering services to all residents in Hong Kong (>7 million people). 
CDARS contains patients’ data, including demographic information, diagnosis, procedures, 
prescription, laboratory tests, admission and discharge information.  The database has captured 
data since 1993 from all public hospitals, institutions and outpatient clinics under HA, and has 
been used to conduct high-quality local and multinational pharmacoepidemiological studies.11, 12  
In addition to the clinical data from CDARS, medical notes written by clinicians were also 
reviewed to evaluate the drug causality of the cases. The medical notes were obtained from the 
electronic database in HA, which contains scanned copies of the written medical notes. 
Case identification and selection 
Potential cases of agranulocytosis, from 1 January 2004 to 31 December 2013, were first identified 
in CDARS by International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) 288.0 Neutropenia. Neutropenia was defined as ANC less than 1.5 x 109/L and was 
subdivided into Grade 1 to 4 by the Common Terminology Criteria for Adverse Events Ver. 4.0.13 
Agranulocytosis was defined as Grade 4 neutropenia (ANC less than 0.5 x 109/L). To confirm the 
cases of agranulocytosis, laboratory test records were reviewed. Only patients who had a record of 
ANC less than 0.5 x 109/L with a normal hemoglobin level (≥10 g/dL) and platelet count (100 x 
109/L) were selected. The index day was deemed to be the day on which ANC<1.5 x 109/L, a 
threshold of abnormal neutrophil count in circulating blood. We excluded patients who met at least 
one of the following criteria: 1) receiving chemotherapy, radiotherapy, or the use of drugs for 
malignant disease and immunosuppression (British National Formulary 8.1 to 8.3) within 6 months 
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of index day; 2) having systemic diseases that could lower the neutrophil count (lymphoma, 
leukemia, myelodysplastic syndromes, hepatitis, HIV, systemic lupus erythematosus, rheumatoid 
arthritis, vitamin B12 deficiency, aplastic anemia, myelofibrosis, Crohn’s disease, hypersplenism, 
infection, Kikuchi’s disease, Sjogren’s syndrome, chronic neutropenia, cyclic neutropenia, and 
congenital neutropenia); 3) age of onset younger than 3; 4) insufficient laboratory records and 
clinical data for evaluation. 
Incidence rate and mortality 
Incidence rate was calculated by dividing the number of cases by the total person-year during the 
study. The total person-year was estimated by summation of person-year of each year, which is 
calculated by the mid-year population data from the Census and Statistics Department, Hong Kong 
(http://www.censtatd.gov.hk/). We further calculated age- and sex- specific incidence to 
investigate any increased rate in subgroup populations. All-cause mortality of patient with a 
validated diagnosis of agranulocytosis during hospitalization was calculated. 
Drug exposure and incidence 
All prescription records and medical notes written by clinicians were reviewed to evaluate the 
causality between the drug intake and disease occurrence. We applied the World Health 
Organization causality assessment14 and categorised the cases into “certain”, “probable”, 
“possible”, “unlikely” according to 4 aspects: 1) a plausible time relationship to drug intake; 2) the 
absence of other causes or other drugs that induced the disease; 3) a reasonable response to the 
withdrawal of drug (positive dechallenge); 4) an existence of rechallenge or a positive result of 
drug dependent antibody testing against neutrophil granulocytes. A plausible time relationship was 
defined as the occurrence of disease during the drug therapy, or within 1 month after drug 
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withdrawal. A reasonable response to the withdrawal of drug was defined as neutrophil count 
returned to 1.5 x 109/L or higher. Cases categorized into certain and probable were selected for 
analysis.  Cases with more than one suspected drug were grouped as multiple drugs and were not 
included in the drug analysis.  
For each associated drug, the total number of patients prescribed the drug from 2004 - 2013 were 
obtained to calculate the drug-specific incidence of agranulocytosis. 
Case-Control analysis 
A case-control analysis was conducted to estimate the risk of drug that is associated with 
agranulocytosis. Controls were selected from patients visiting the out-patients clinics. For each 
case, four controls were matched on sex, exact age, and calendar year of the index day. The index 
day of control was the day visiting out-patient clinic. Same exclusion criteria as cases were applied 
to controls. Controls were considered as exposed to a drug if the drug had been prescribed in a 
window of 30 days preceding index day. 
Statistical analysis 
Continuous variables were presented as mean with S.D. or median with range and categorical 
variables were showed as frequency with percentage. The incidence rate with 95% confidence 
interval (CI) was estimated using Poisson distribution. Given the small number of cases, the exact 
method for conditional logistic regression was used to calculate odd ratios (ORs) and 95% CI. Age, 
sex, and any concurrent drugs with significant crude OR were adjusted. All calculations were 
performed with R statistical software package (version 3.0.1, www.R-project.org). A two-tailed p 




Overall, 10,062 patients with a new diagnosis of neutropenia were identified in CDARS. Of these, 
4,879 patients were confirmed to have agranulocytosis. After exclusion screening, 311 patients 
were remained for drug causality assessment. Of these, 154 patients with agranulocytosis were 
considered to be certain or probable drug-induced cases. As one patient had two episodes of 
agranulocytosis induced by two different antithyroid drugs (carbimazole and propyl thiouracil), a 
total of 155 cases were included in the analysis (The case screening flow chart is shown in Figure 
1).The mean age of the cases was 51.4 years and over 60% of cases were female. Median length 
of stay was 9 days (range 1 - 123 days). The comorbidity of the cases was reviewed and 
cardiovascular disease (34.8%) was the most common chronic disease found in the cases, followed 
by diabetes (14.2%) and chronic renal diseases (7.1%). (Table 1) 
Incidence rate and mortality 
The age- and sex- specific incidence rate of drug-induced agranulocytosis were shown in Table 2. 
Based on total person-year of 69,875,600 during the study period, the overall incidence rate of 
drug-induced agranulocytosis was estimated to be 2.2 (95% CI 1.9-2.6) cases per million person-
years. Women (incidence rate 2.6, 95% CI 2.1-3.2) were more likely to have the disorder than men 
(incidence rate 1.8, 95% CI 1.4-2.4). In both sexes, the incidence rate increased with age. The 
incidence rate per million person-years in people aged over 65 was 4.6 (95% CI 3.4-5.9), which 
was at least twice higher than people in other age groups (incidence rate 0.5, 95% CI 0.2-1.0 in 
people aged 0-19; 2.1, 95% CI 1.5-2.8 in people aged 20-39; 2.1, 95% CI 1.6-2.8 in people aged 




Among the cases, 6 patients (2 female and 4 male) died during hospitalization. 5 of the patients 
(83.3%) were aged over 60 and all patients had at least one chronic disease. The all-cause mortality 
in patients with drug-induced agranulocytosis was calculated to be 3.9%.  
Drug aetiology 
A total of 59 drugs were identified to have a certain or probable association with agranulocytosis 
(Table 3). Of these, a majority of cases were induced by antithyroid drugs (41.9%), with 
carbimazole (33.5%) to be the most common implicated drug. Antimicrobials (20%) and 
anticonvulsants (10.3%) were the second and third common group of drugs. Among the group of 
antimicrobials, over one-third (41.9%) of the cases were induced by penicillins. Other associated 
drugs included antipsychotics (6.5%), antigout dugs (1.9%), antiplatelet drugs (1.9%), 
antidepressants (1.3%), iron-chelating drugs (1.3%), calcium channel blockers (0.7%), and 
nonsteroidal anti-inflammatory drugs (0.7%). Notably, two cases were associated with traditional 
Chinese medicine (TCM).  
Out of the 134 cases (excluded cases induced by TCM, over-the-counter drug, or multiple 
suspected drugs), agranulocytosis occurred within the first 30 days of drug exposure in 46.3% of 
cases; 46.3% within 31-60 days and 5.2% within 61-90 days. The median (range) exposure time 
to drugs was 33 days (0-1201). Antipsychotics had the longest median exposure duration of 48.5 
days (27-1201), in which one clozapine-induced case had agranulocytosis after 3 years of 
treatment. Antithyroid drugs and anticonvulsants had the median exposure time of 35.5 days (0-




The incidence of agranulocytosis for each specific drug was shown in table 3. Although 
methimazole has the highest incidence proportion of 47.2 cases per 10,000 users (95% CI 1.2 - 
262.8), and incidence rate of 22.9 cases per 10,000 patient-years (95% CI 0.6-127.8), estimation 
was based on one case only. For drugs with at least 3 cases reported, carbimazole, propyl thiouracil, 
and clozapine have a higher incidence (incidence proportion 9.2 - 19.8 cases per 10,000 users; 
incidence rate 3.6 - 4.9 cases per 10,000 user-years), compared to phenytoin, penicillins, 
cephalosporins, and rifampicin (incidence proportion 0.7 - 1.4; incidence rate 0.1 - 0.8). 
The four most common drug classes (antithyroid drugs, antimicrobials, anticonvulsants, and 
antipsychotics) were included in the case-control analysis. 488 controls were matched with 122 
cases. As expected, carbimazole had the highest risk (adjusted OR 416.7, 95% CI 51.5-3372.9) of 
agranulocytosis, and followed by clozapine (adjusted OR 154.6 (95%CI 12.9-1853.9), and propyl 
thiouracil (adjusted OR 40.7, 95% CI 5.2–316.8). Other drugs with significant increased risk 
included penicillins, cephalosporins, and phenytoin. (Table 4) 
Discussion 
Our study evaluated the epidemiological profile, including incidence, drug aetiology, and mortality 
of drug-induced agranulocytosis, in Hong Kong Chinese using a population-based health database 
in Hong Kong. Our data were consistent with previous studies in other populations showing a 
relatively low incidence and mortality. 
In the early 1980s, the International Aplastic Anemia and Agranulocytosis Study (IAAAS) has 
estimated the incidence of agranulocytosis in European countries to be 6.2 cases per million per 
year with a large difference across the regions, ranging from 1.7 in Milan, Italy to 9.0 in Budapest, 
Hungary.5 Over the years, several population-based studies conducted in Caucasians have reported 
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similar incidence, ranging from 2.0 - 9.2 cases per million per year.4, 15-18 Compared to these studies, 
we observed a relatively lower incidence with slight increase over the years. The low incidence of 
agranulocytosis was also reported in Thai population (0.7 cases per million per year),19 suggesting 
that Asians may have a lower incidence of drug-induced agranulocytosis compared to Caucasians.  
Old age was commonly reported as a risk factor for agranulocytosis as the incidence rates reported 
in the literature were consistent in the  age group of 20-39 and 40-59, while the rate in the group 
aged over 60 was reported to be twice higher. A Thai study by Shapiro et al estimated an incidence 
rate of 3.6 cases per million per year at aged over 60, which was three times higher than other age 
groups19. Studies suggested that the high risk in older patients could be attributed to the increased 
number of concurrent drugs patients might be taking. We investigated this potential association 
with our data and found that the mean±sd number of concurrent drugs in patients at age over 60 
was 10.7±5.0 while at age below 60 was 5.1±4.4. A significant difference (p<0.001) was observed. 
It is possible that polypharmacy may increase the potential of drug-drug interactions and hence 
increase the risk of agranulocytosis. A case report described a patient with 3-year treatment of 
clozapine developed agranulocytosis after the addition of valproic acid, an anticonvulsant.20 
Although currently there are limited studies on exploring the potential impact of drug-drug 
interactions on the occurrence of agranulocytosis, clinicians should be aware of the higher risk of 
adverse drug events in patients with multiple drug exposures.  
The ratio of women to men in our study was 1.6 to 1 and a higher incidence rate was estimated in 
women, which was similar to previous studies.3, 15 More women were observed to have the higher 
incidence probably due to the drug aetiology profile, as antithyroid drugs were the most common 
12 
 
drugs associated with agranulocytosis in our population, and hyperthyroidism is predominantly 
present in women.21 
A broad-spectrum of drug aetiology profile was observed in the current study, which was generally 
comparable with other populations. In our study, we found that antithyroid drugs were the most 
common drugs to be associated with a high risk of agranulocytosis, which is a phenomenon that 
has been well-documented in the literature. The IAAAS estimated a relative risk of 102 (95% CI 
38 - 275) in antithyroid drugs,22 whereas study by van der Klauw et al reported a relative risk of 
114.8 (95% CI 60.5 – 218.6).15 In accordance with these studies, we reported large ORs of 416.7 
and 40.7 in carbimazole and propyl thiouracil respectively.   
Antimicrobials were the second most common drug class but only penicillins and cephalosporins, 
both belong to the group of beta-lactams, had an elevated risk of agranulocytosis. Several studies 
reported the association of beta-lactams and agranulocytosis and the ORs were estimated to be 3.1 
- 4.7 cases per million.4, 15, 17 Compared with previous studies, we observed a higher risk 
(penicillins, adjusted OR 8.1; cephalosporins, adjusted OR 21.4). However, an important point to 
note is that beta-lactams can be prescribed for the treatment of potential infections associated with 
agranulocytosis, without the data on the date of onset of infection which possibly prompted the 
prescribing of penicillin, some of the cases identified may actually have the exposure to penicillin 
after the onset of agranulocytosis. We therefore cannot exclude the possibility of overestimating 
the risk of agranulocytosis associated with the use of beta-lactams in our study. 
One case of oxcarbazepine-induced agranulocytosis was identified in this study. Oxcarbazepine, a 
10-keto analogue of carbamazepine, is one of the newer antiepileptic drugs. Like carbamazepine, 
the major adverse event of oxcarbazepine is cutaneous adverse reactions such as Stevens-Johnson 
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Syndrome. To date, only seven cases were reported in the literatures to be oxcarbazepine-induced 
blood dyscrasias23-29 but none of the cases was agranulocytosis. Thus, our study reported the first 
oxcarbazepine-induced agranulocytosis in the literature. Interestingly, among eight 
oxcarbazepine-induced blood dyscrasias (including our case), four occurred in Asians24, 26, 27 
(including 3 Chinese and 1 Asian-American), suggesting that genetic predisposition may play a 
role on the pathogenesis of oxcarbazepine-induced blood dyscrasias, warranting further 
investigation. 
The exposure period of each drug groups were comparable with other studies.2 Over 90% of our 
cases developed agranulocytosis within the first three months of drug treatment, with half of the 
cases having exposed to the drug for more than one month. However, there were few reports of 
late onset of agranulocytosis after prolonged treatment of clozapine30, 31 and antithyroid drugs32. 
In our study, we also found one case with delayed onset after three years of clozapine treatment. 
In view of the long exposure period before onset of agranulocytosis, debate over the effectiveness 
of routine blood monitoring has been discussed for years. Tajiri et al showed that 43 out of 55 
antithyroid drug-induced cases were asymptomatic and detected during routine blood monitoring, 
supporting the need of regular monitoring.33 In contrast, study by Nakamura et al reported that 
more than half of the antithyroid drugs-associated cases had normal blood count in two weeks 
before onset of agranulocytosis, arguing that routine monitoring of blood cell count had little value 
in predicting the disease.34 In our cases, all nine patients with clozapine-induced cases had blood 
monitoring on a weekly basis. However, only three cases showed a gradual decrease in ANC while 
four cases had a sharp drop compared to the last record. For antithyroid drug-induced case, over 
80% of them did not have blood monitoring during the exposure period. Even if the blood counts 
were monitored, the intervals were so long that any gradual decrease could hardly be detected. It 
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seems that routine blood monitoring to detect agranulocytosis is not promising but whether it can 
allow early detection and hence lower the severity of the disease, in terms of infection rate, length 
of stay and complications, are worth investigating. 
The mortality of drug-induced agranulocytosis in European populations was reported to be 4.8 - 
9.1%4-6, 15, 35 and has a decreasing trend in recent years.2 Risk factors associated with mortality in 
agranulocytosis cannot be investigated in current study due to small number of deaths but we found 
that most of them were older patients (aged over 65) with at least one chronic disease. Compared 
to European populations, our study estimated a lower mortality which may be due to a couple of 
reasons. First of all, some European studies were conducted 20-30 years ago when treatment for 
agranulocytosis was not as advanced as nowadays, possibly resulting in poorer treatment outcomes 
for the patients. Furthermore, drug aetiology profiles were different and it seems that some drugs, 
particularly metamizole, induced more severe cases than the others. The IAAAS reported a 9% 
fatality rate among cases associated with analgesics (mainly metamizole)5 but only 2% in 
antithyroid drug-associated cases.22 Similarly, a German study on metamizole-associated 
agranulocytosis reported a high fatality rate of 23%.36 Our cases may be less severe as none was 
induced by metamizole and most of them were induced by antithyroid drugs.  
Apart from old age and the female gender, genetic predisposition is also a risk factor of 
agranulocytosis. Study by Goldstein et al had reported that two human leukocyte antigen (HLA) 
alleles in HLA-DQB1 and HLA-B were associated with clozapine-induced agranulocytosis.37 A 
Taiwanese study identified strong markers HLA-B*38:02 and HLA-DRB1*08:03 in antithyroid 
drugs-induced agranulocytosis.38  Another study in Hong Kong Chinese population also reported 
a strong association between HLA-B*38:02 and antithyroid drugs-induced agranulocytosis.39  In 
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European population, another marker, HLA-B*27:05, was found in antithyroid drugs-induced 
agranulocytosis.40 Given the effectiveness of genetic screening in preventing rare adverse drug 
reactions,41, 42 it is worth considering the incorporation of genetic screening in future clinical 
guidelines. 
Our study has several strengths and limitations. First, the database CDARS contains a 
comprehensive clinical data and it captures patients from all the publicly-funded hospitals and 
ambulatory clinics, allowing a population-based analysis of the disorder. Second, the controls were 
matched with age, sex, and index day for a comparable characteristics and drug exposure period 
to the cases, minimising the confounding bias. Limitations in the study included the small sample 
size, given a rare disease, which leaded to a wide CI in the risk estimate. In addition, we cannot 
exclude the possibility of under diagnosis and recording. Nevertheless, as CDARS is used for 
clinical management, it is believed that such an important clinical diagnosis is unlikely to be 
missed. Furthermore, during the drug causality assessment, cases were excluded due to limited 
drug exposure records. These patients may have the prescription of the associated drug from the 
private clinics or hospitals, which were not covered by CDARS. As a result, an underestimation 
of incidence cannot be ruled out. 
In conclusion, the incidence and mortality in Hong Kong Chinese was relatively lower compared 
with Caucasians. The drug aetiology profile was comparable with those in literatures, and 
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Table 1 Characteristics of patient with drug-induced agranulocytosis 
Characteristics   Case (n=155) 
Female, n (%)  95 (61.3) 
Age 
Mean ± SD. 








Chronic disease, n (%) 
 Cardiovascular diseases  
 Diabetes  










Community acquired, n (%)  84 (54.2) 
Length of stay, median (range)  9 (1-123) 





Table 2 Age- and Sex- specific incidence rate^ of drug-induced agranulocytosis from 2004 to 2013. 
Age 














0 - 19  3 0.5 (0.1–1.4)  3 0.4 (0.1-1.3)  6 0.5 (0.2-1.0) 
20 - 39  33 2.8 (1.9–3.9)  11 1.2 (0.6-2.1)  44 2.0 (1.5-2.8) 
40 - 59  30 2.5 (1.7-3.5)  19 1.7 (1.0-2.7)  49 2.1 (1.6-2.8) 
≥60  29 4.5 (3.0-6.5)   27 4.6 (3.0-6.7)  56 4.6 (3.4-5.9) 
Total  95 2.6 (2.1-3.1)  60 1.8 (1.4-2.4)  155 2.2 (1.9-2.6) 





Table 3 Drug aetiology profile and incidence from 2004 – 2013 for specific drug 
Drug class Drug Cases, n No. of drug 
users 
Incidence proportion 
per 10,000 users (95% CI) 
Incidence rate 
per 10,000 user-years (95% CI) 
Antithyroid drugs Carbimazole 52 56,249 9.2 (6.9-12.1) 3.6 (2.7-4.8) 
 Propyl thiouracil 12 10,441 11.5 (5.9-20.1) 4.9 (2.5-8.6) 
 Methimazole 1 212 47.2 (1.2-262.8) 22.9 (0.6-127.8) 
Antimicrobials Penicillins^ 13 124,294 1 (0.6-1.8) 0.1 (0.1-0.2) 
 Cephalosporins∆ 8 112,973 0.7 (0.3-1.4) 0.1 (0.1-0.2) 
 Rifampicin 4 41,401 1 (0.3-2.5) 0.8 (0.2-1.9) 
 Vancomycin 2 56,825 0.4 (<0.1-1.3) 0.3 (<0.1-1.1) 
 Meropenem 2 45,078 0.4 (0.1-1.6) 0.4 (0.1-1.4) 
 Doxycycline 1 76,095 0.1 (<0.1-0.7) 0.1 (<0.1-0.6) 
 Cotrimoxazole 1 93,239 0.1 (<0.1-0.6) 0.1 (<0.1-0.5) 
Anticonvulsants Phenytoin 9 62,473 1.4 (0.7-2.7) 0.6 (0.3-1.2) 
 Lamotrigine 2 5,079 3.9 (0.5-14.2) 1.2 (0.1-4.1) 
 Carbamazepine 2 28,399 0.7 (0.1-2.5) 0.2 (<0.1-0.7) 
 Oxcarbazepine 1 1,256 8 (0.2-44.4) 2.5 (0.1-14.0) 
 Topiramate 1 2,907 3.4 (0.1-19.2) 1.0 (<0.1-5.6) 
 Gabapentin 1 60,573 0.2 (<0.1-0.9) 0.1 (<0.1-0.5) 
Antipsychotics Clozapine 9 4,551 19.8 (9-37.5) 3.6 (1.6-6.8) 
 Quetiapine 1 41,296 0.2 (<0.1-1.3) 0.1 (<0.1-0.6) 
Antigout drugs Allopurinol 2 100,285 0.2 (<0.1-0.7) 0.1 (<0.1-0.2) 
 Colchicine 1  19,5458 0.1 (<0.1-0.3) <0.1 (<0.1-0.1) 
Traditional Chinese 
Medicine 
- 2  - -  -  
Others - 5 - -  -  
Multiple drugs - 18 - -  -  
^Penicillins include piperacillin/piperacillin+tazobactam (9), cloxacillin (3), and Ticarcillin/clavulanic acid (1). 
∆Cephalosporins include ceftriaxone (6), cefuroxime (1), and cefotaxime (1). 





Table 4 Risk estimate of drug associated with agranulocytosis  




Crude odd ratio 
(95%CI) 
Adjusted odd ratio 
( 95%CI)^ 
Antithyroid drugs Carbimazole 52 5 198.1 (27.4 – 1433.6) 416.7 (51.5 – 3372.9) 
 Propyl thiouracil 12 1 48.0 (6.2 – 369.2) 40.7 (5.2 – 316.8) 
 Methimazole 1 0 - - 
Antimicrobials Penicillins 13 20 3.0 (1.4 – 6.5) 8.1 (2.8 – 23.4) 
 Cephalosporins 8 4 8.0 (2.4 – 26.6) 21.4 (3.9 – 116.0) 
 Rifampicin 4 0 - - 
 Vancomycin 2 1 8.0 (0.7-88.2) - 
 Meropenem 2 0 - - 
 Cotrimoxazole 1 0 - - 
 Doxycycline 1 0 - - 
Anticonvulsants Phenytoin 9 5 8.5 (2.6 – 27.7) 31.6 (4.9 - 201.9) 
 Carbamazepine 2 3 2.7 (0.5 – 16.0) - 
 Lamotrigine 2 1 8.0 (0.7 – 88.2) - 
 Gabapentin 1 6 0.7 (0.1 – 5.5) - 
 Oxcarbazepine 1 0 - - 
 Topiramate 1 0 - - 
Antipsychotics Clozapine 9 1 36.0 (4.6 – 284.2) 154.6 (12.9 - 1853.9) 
 Quetiapine 1 3 1.3 (0.1 – 12.8) - 
*drug that was not exposed in control group were excluded in the analysis 
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